Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-08-09
2002-08-27
Vollano, Jean F. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S640000, C514S645000, C564S300000, C564S265000
Reexamination Certificate
active
06441032
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to novel &agr;-aryl-N-alkylnitrones and their use as therapeutic agents and analytical reagents. More particularly, this invention concerns novel &agr;-aryl-N-alkylnitrones and their use as therapeutics for treating and/or preventing neurological, autoimmune and inflammatory conditions in mammals and as analytical reagents for detecting free radicals.
2. State of the Art
Alzheimer's disease is a neurodegenerative condition in which nerve cells in the brain are systematically destroyed resulting in progressive memory loss, mental confusion and ultimately death. The National Institute on Aging (NIA) has recently estimated that about 4 million people in the United States are currently afflicted with Alzheimer's disease. At present, there is no treatment that effectively prevents the disease or reverses its symptoms.
In recent years, significant progress has been made in understanding the pathogenesis of Alzheimer's disease. For example, it is now known that patients with Alzheimer's disease develop amyloid plaque deposits around and between the nerve cells of their brain. These plaque deposits are made up of fibrillar aggregates of a small peptide called amyloid &bgr;-peptide or A&bgr;. The plaque deposits initially form in the hippocampus and cortical regions of the brain (areas associated with memory and cognition) and then spread to other areas as the disease progresses. The deposition of fibris and plaques is also followed by inflammation of the surrounding support cells. called glia, which may lead to further loss of neurons. Eventually, the nerve cells in the brains of most Alzheimer's patients develop tangles of a microtubule-associated protein, called tau, which are believed to be a response by the nerve cells to damage.
Progress in understanding the underlying mechanisms of Alzheimer's disease has led to the development of various in vitro and in vivo models to identify compounds effective for preventing and/or treating Alzheimer's disease and other neurodegenerative conditions. In one such in vitro model, compounds are evaluated for their ability to intervene in A&bgr;(1-40) or A&bgr;(1-42) beta-pleated sheet formation. Since the deposition of amyloid &bgr;-peptide is associated with the development of Alzheimer's disease. compounds which effectively disrupt the formation of A&bgr;(1-40) beta-pleated sheets are potentially useful for preventing and/or reversing Alzheimer's disease-related amyloid deposits.
In another in vitro model, compounds are evaluated for their ability to protect against A&bgr;(25-35)-induced neuronal cell loss in rat embryonic hippocampal neuronal/astrocyte cultures. As discussed above, patients with Alzheimer's disease suffer a progressive loss of neuronal cells. Accordingly, compounds which are effective in this in vitro test are potentially useful for reducing or preventing neuronal cell loss in patients afflicted with Alzheimer's disease or other neurodegenerative conditions.
A third in vitro Alzheimer's disease model is based on the observation that &bgr;-amyloid increases the release of cytokines, such as interleukin-1&bgr; (IL-1&bgr;), interleukin-6 (IL-6) and tumor necrosis factor-&agr; (TNF&agr;), in human monocyte cells induced with lipopolysaccharide (LPS). IL-1&bgr;, IL-6 and TNF&agr; are proteins associated with inflammatory and immune responses. As previously mentioned, the deposition of fibrils in the brains of Alzheimer's patients is associated with inflammation of the surrounding support cells. See, S. D. Yan et al.,
Proc. Natl. Acad. Sci. USA,
94, 5296 (1997). Thus, compounds effective in this in vitro test are potentially useful for reducing and/or preventing the inflammation associated with Alzheimer's disease.
Additionally, elevated levels of IL-1&bgr;, IL-6, TNF&agr; and other cytokines are associated with a wide variety of inflammatory and autoimmune conditions, including septic shock, rheumatoid arthritis, erythema nodosum leprosy, meningococcal meningitis, multiple sclerosis, systemic lupus and the like. See, L. Sekut et al.,
Drug News Perspect.
1196, 9, 261; and A. Waage et al.,
J. Exp. Med.
1989, 170, 1859-1867. Accordingly, compounds which inhibit the production of such cytokines are potentially useful for treating such inflammatory and autoimmune conditions.
Similarly, various in vivo disease models are available for identifying compounds useful for preventing and/or treating neurodegenerative, autoimmune and inflammatory conditions. One such in vivo disease model is based on the observation that mammals suffer cognitive impairment when A&bgr;(25-35) and ibotenate are injected into the hippocampus of their brain. Since amyloid &bgr;-peptide deposits are associated with Alzheimer's disease, compounds which effectively reduce the cognitive impairment caused by A&bgr;(25-35)/ibotenate are potentially useful for the prevention and/or treatment of Alzheimer's disease and other neurodegenerative conditions. Another in vivo disease model is based on the observation that certain strains of autoimmune mice develop cognitive deficits as they mature. See, for example, Forster et al.,
Behav. Neural Biology
1988, 49, 139-151. Thus, compounds which prevent or reduce such cognitive deficits are potentially useful for preventing and/or treating neurodegenerative and autoimmune conditions.
It has now been discovered that certain novel &agr;-aryl-N-alkylnitrone compounds effectively inhibit the formation of A&bgr;(1-42) beta-pleated sheets and/or protect against neuronal cell loss and/or inhibit the release of cytokines, such as IL-1&bgr; and TNF&agr;. Additionally, in in vivo tests, these compounds have been found to reduce the cognitive impairment caused by A&bgr;(25-35)/ibotenate and to reduce the cognitive deficits that develop in certain strains of autoimmune mice. Accordingly, such compounds are useful for the prevention and/or treatment of neurodegenerative, autoimmune and inflammatory conditions in mammals.
The &agr;-aryl-N-alkylnitrone compounds of this invention are also useful as analytical reagents for detecting free radicals. In this regard, the compounds of this invention function as “spin traps” by reacting with unstable free radicals to form relatively stable free radical spin adducts which are observable by electron spin resonance (ESR) spectroscopy. Accordingly, when used as spin traps, the compounds of this invention allow free radicals to be identified and studied using ESR and related techniques.
SUMMARY OF THE INVENTION
This invention provides novel &agr;-aryl-N-alkylnitrone compounds which are useful as therapeutics for treating and/or preventing neurological, autoimmmune and inflammatory conditions in mammals and as analytical reagents for detecting free radicals. In particular, the compounds of this invention are useful for preventing and/or treating Alzheimer's disease.
Accordingly, in one of its composition aspects, this invention is directed to compounds of formula I:
wherein
R
1
is selected from the group consisting of alkoxy, alkaryloxy, alkcycloalkoxy, aryloxy, and cycloalkoxy;
R
2
is selected from the group consisting of hydrogen, alkoxy, alkcycloalkoxy, cycloalkoxy and halogen, or when R
1
and R
2
are attached to adjacent carbon atoms, R
1
and R
2
may be joined together to form an alkylenedioxy group;
R
3
is selected from the group consisting of hydrogen, alkoxy, alkcycloalkoxy, cycloalkoxy and halogen;
R
4
is selected from the group consisting of hydrogen and alkyl;
R
5
is selected from the group consisting of alkyl having at least 3 carbon atoms, substituted alkyl having at least 3 carbon atoms and cycloalkyl;
provided that:
(i) when R
2
and R
3
are independently hydrogen or methoxy, R
1
is not methoxy;
(ii) when R
2
, R
3
and R
4
are hydrogen and R
5
is tert-butyl, then R
1
is not 4-n-butoxy, 4-n-pentyloxy or 4-n-hexyloxy;
(iii) when R
2
, R
3
and R
4
are hydrogen and R
5
is isopropyl, then R
1
is not 4-ethoxy;
(
Dykman Alina
Kelleher Judith A.
Levell Julian
Maples Kirk R.
Wilcox Allan L.
Burns Doane , Swecker, Mathis LLP
Centaur Pharmaceuticals, Inc.
Vollano Jean F.
LandOfFree
Alpha-(4-Ethoxyphenyl)-N-tert-butylnitrone, pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-(4-Ethoxyphenyl)-N-tert-butylnitrone, pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-(4-Ethoxyphenyl)-N-tert-butylnitrone, pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2945081